Aza-aryl 1H-pyrazol-1-yl benzene sulfonamides

Patent metadata

Field	Value
Publication number	US-10137120-B2
Application number	US-201414541637-A
Country	US
Kind code	B2
Filing date	Nov 14, 2014
Priority date	Feb 29, 2012
Publication date	Nov 27, 2018
Grant date	Nov 27, 2018

Abstract

Compounds are provided that act as potent antagonists of the CCR(9) receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR(9). The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR(9)-mediated diseases, and as controls in assays for the identification of CCR(9) antagonists.

First claim

The invention claimed is:

1. A compound of the following formula:

2. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound of claim 1 .

3. A compound of the following formula:

or a pharmaceutically acceptable salt thereof.

4. The sodium salt of the compound of claim 3 .

5. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound or pharmaceutically acceptable salt thereof of claim 3 .

6. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the sodium salt of claim 4 .

7. A method for treating a CCR(9)-mediated disease or condition in a subject, the method comprising administering to the subject in need thereof a therapeutically-effective amount of a compound of claim 3 , wherein the CCR(9)-mediated disease or condition is selected from the group consisting of ulcerative colitis, Crohn's disease, inflammatory bowel disease, asthma, graft rejection, immune mediated food allergies, celiac disease, primary sclerosing cholangitis, and graft-v-host disease.

8. The method according to claim 7 , wherein the CCR(9)-mediated disease or condition is ulcerative colitis.

9. The method according to claim 7 , wherein the CCR(9)-mediated disease or condition is Crohn's disease.

10. The method according to claim 7 , wherein the CCR(9)-mediated disease or condition is primary sclerosing cholangitis.

11. The method according to claim 10 , wherein the primary sclerosing cholangitis is subsequent to or associated with an inflammatory bowel disease.

12. The method according to claim 7 , wherein the subject is a human.

13. The method according to claim 7 , where the administering is oral, parenteral, rectal, transdermal, sublingual, nasal or topical.

14. The method according to claim 7 , further comprising administering an anti-inflammatory or analgesic agent.

15. The method according to claim 14 , wherein the anti-inflammatory or analgesic agent is selected from the group consisting of an opiate agonist, lipoxygenase inhibitor, cyclooxygenase inhibitor, interleukin inhibitor, NMDA antagonist, inhibitor of nitric oxide or inhibitor of nitric oxide synthesis, aminosalicylates, corticosteroids or other immunosuppressive drugs, non-steroidal antiinflammatory agent, cytokine-suppressing antiinflammatory agent, biological TNF sequestrant, biological agents which target α4β7, ACE2 inhibitors, protein kinase C inhibitors, and a steroidal analgesic.

16. The method according to claim 14 , wherein the anti-inflammatory or analgesic agent is an 5-lipoxygenase inhibitor, cyclooxygenase-2 inhibitor, interleukin-1 inhibitor, HMG-CoA reductase inhibitor, or β2-agonist.

17. The method according to claim 14 , wherein the anti-inflammatory or analgesic agent is acetaminophen, aspirin, codeine, fentanyl, ibuprofen, indomethacin, ketorolac, morphine, naproxen, phenacetin, piroxicam, sufentanyl, sunlindac, or tenidap.

18. The method according to claim 7 , further comprising administering a compound selected from the group consisting of a pain reliever, potentiator, H2-antagonist, decongestant, antitussive, diuretic, sedating or non-sedating antihistamine, very late antigen (VLA-4) antagonist, immunosuppressant, EDG receptor agonist, steroid, non-steroidal anti-asthmatic agent, leukotriene antagonist, leukotriene biosynthesis inhibitor, inhibitor of phosphodiesterase type IV (PDE-IV), cholesterol lowering agent, sequestrant, cholesterol absorption inhibitor, anti-diabetic agent, α-glucosidase inhibitor, a β2-agonist, an HMG-CoA reductase inhibitor and glitazone.

19. The method according to claim 18 , wherein the compound is caffeine, simethicone, aluminum or magnesium hydroxide, pseudophedrine, codeine, cyclosporine, tacrolimus, rapamycin, FK-506, or insulin.

Assignees

• Chemocentryx Inc

Inventors

• Chen Xi
• Fan Junfa
• Fan Pingchen
• Krasinski Antoni
• Li Lianfa
• Lui Rebecca M
• Mcmahon Jeffrey P
• Powers Jay P
• Zeng Yibin
• Zhang Penglie

Classifications

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title